Literature DB >> 19364849

Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.

Arnold Louie1, Christine Fregeau, Weiguo Liu, Robert Kulawy, G L Drusano.   

Abstract

The dose choice for Pseudomonas aeruginosa remains a matter of debate. The actual exposure targets required for multilog killing of organisms at the primary infection site have not been delineated. We studied Pseudomonas aeruginosa PAO1 using a murine model of pneumonia. We employed a large mathematical model to fit all the concentration-time data in plasma and epithelial lining fluid (ELF) as well as colony counts in lung simultaneously for all drug doses. Penetration into ELF was calculated to be approximately 77.7%, as indexed to the ratio of the area under the concentration-time curve for ELF (AUC(ELF)) to the AUC(plasma). We determined the ELF concentration-time profile required to drive a stasis response as well as 1-, 2-, or 3-log(10)(CFU/g) kill. AUC/MIC ratios of 12.4, 31.2, 62.8, and 127.6 were required to drive these bacterial responses. Emergence of resistance was seen only at the two lowest doses (three of five animals at 50 mg/kg [body weight] and one of five animals at 100 mg/kg). The low exposure targets were likely driven by a low mutational frequency to resistance. Bridging to humans was performed using Monte Carlo simulation. With a 750-mg levofloxacin dose, target attainment rates fell below 90% at 4 mg/liter, 1 mg/liter, and 0.5 mg/liter for 1-, 2-, and 3-log kills, respectively. Given the low exposure targets seen with this strain, we conclude that levofloxacin at a 750-mg dose is not adequate for serious Pseudomonas aeruginosa pneumonia as a single agent. More isolates need to be studied to make these observations more robust.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19364849      PMCID: PMC2715581          DOI: 10.1128/AAC.00006-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Arnold Louie; Mark R Deziel; Weiguo Liu; Robert Leary; George L Drusano
Journal:  J Infect Dis       Date:  2005-07-05       Impact factor: 5.226

2.  A sensitive assay of amoxicillin in mouse serum and broncho-alveolar lavage fluid by liquid-liquid extraction and reversed-phase HPLC.

Authors:  Xiaoli Du; Chonghua Li; Heather K Sun; Charles H Nightingale; David P Nicolau
Journal:  J Pharm Biomed Anal       Date:  2005-09-15       Impact factor: 3.935

3.  Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.

Authors:  V H Tam; A Louie; T R Fritsche; M Deziel; W Liu; D L Brown; L Deshpande; R Leary; R N Jones; G L Drusano
Journal:  J Infect Dis       Date:  2007-05-02       Impact factor: 5.226

4.  Pseudomonas aeruginosa acquires biofilm-like properties within airway epithelial cells.

Authors:  Raquel Garcia-Medina; W Michael Dunne; Pradeep K Singh; Steven L Brody
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

5.  Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.

Authors:  C A Peloquin; T J Cumbo; D E Nix; M F Sands; J J Schentag
Journal:  Arch Intern Med       Date:  1989-10

6.  Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae.

Authors:  C T Ong; P K Dandekar; C Sutherland; C H Nightingale; D P Nicolau
Journal:  Chemotherapy       Date:  2005-10-13       Impact factor: 2.544

7.  Early predictors for infection recurrence and death in patients with ventilator-associated pneumonia.

Authors:  Alain Combes; Charles-Edouard Luyt; Jean-Yves Fagon; Michel Wolff; Jean-Louis Trouillet; Jean Chastre
Journal:  Crit Care Med       Date:  2007-01       Impact factor: 7.598

8.  Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens.

Authors:  Thomas P Lodise; Sandra Preston; Vijay Bhargava; Andre Bryskier; Roomi Nusrat; Sonny Chapel; Manichan Rangaraju; George L Drusano
Journal:  Diagn Microbiol Infect Dis       Date:  2005-05       Impact factor: 2.803

9.  Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

Authors:  M P Fink; D R Snydman; M S Niederman; K V Leeper; R H Johnson; S O Heard; R G Wunderink; J W Caldwell; J J Schentag; G A Siami
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.

Authors:  Somvadee Laohavaleeson; Pamela R Tessier; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

View more
  13 in total

1.  Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.

Authors:  Arnold Louie; Weiguo Liu; Michael VanGuilder; Michael N Neely; Alan Schumitzky; Roger Jelliffe; Steven Fikes; Stephanie Kurhanewicz; Nichole Robbins; David Brown; Dodge Baluya; George L Drusano
Journal:  J Infect Dis       Date:  2014-10-31       Impact factor: 5.226

Review 2.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.

Authors:  G L Drusano; Arnold Louie; Alasdair MacGowan; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

Review 3.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

4.  Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?

Authors:  Brad Spellberg; Robert A Bonomo
Journal:  Crit Care Med       Date:  2015-06       Impact factor: 7.598

5.  Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia.

Authors:  G L Drusano; B Vanscoy; W Liu; S Fikes; D Brown; A Louie
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

6.  The Nonantibiotic Macrolide EM703 Improves Survival in a Model of Quinolone-Treated Pseudomonas aeruginosa Airway Infection.

Authors:  Gopinath Kasetty; Ravi K V Bhongir; Praveen Papareddy; Heiko Herwald; Arne Egesten
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

7.  Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model.

Authors:  G L Drusano; Christine Fregeau; Weiguo Liu; D L Brown; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

8.  Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia.

Authors:  Yoriko Harigaya; Jürgen B Bulitta; Alan Forrest; George Sakoulas; Alan J Lesse; Joseph M Mylotte; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

9.  Time-kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin.

Authors:  A Safarika; I Galani; A Pistiki; E J Giamarellos-Bourboulis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-06       Impact factor: 3.267

10.  Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.

Authors:  Arnold Louie; Weiguo Liu; Steven Fikes; David Brown; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.